CG Oncology, Inc.
CG Oncology, Inc. (CGON): 33 pipeline candidates · 40 upcoming catalysts · ~54 mo cash runway · 128 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
54.4 months
D/E 0.04 · 0% dilution
Lead: Phase 3
33 candidates
40 upcoming, next in ~287d
0 buys · 6 sells (180d)
A transparent, data-derived signal for CG Oncology, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$5.3B
Cash
$33.7M
Quarterly Burn
$56.9M
Runway
54.4 mo
Revenue
$1.1M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (33 candidates)
| Drug | Phase |
|---|---|
| Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5 | Phase 2 |
| adjuvant chemotherapy + ovarian function suppression | Phase 3 |
| ADSTILADRIN | — |
| astx727 | Phase 1 |
| avelumab | Phase 3 |
| cabozantinib | Phase 2 |
| Cetrelimab | Phase 3 |
| cretostimogene | Phase 3 |
| cretostimogene grenadenorepvec | Phase 3 |
| eribulin | Phase 2 |
Showing 10 of 33 candidates. Sign up for full pipeline.
Upcoming Catalysts (40)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
235
Total value held
$5.05B
| Holder | Shares | Value |
|---|---|---|
| rtw investments, lp | 6,984,808 | $472.7M |
| vanguard capital management llc | 6,067,250 | $410.6M |
| wellington management group llp | 5,371,232 | $363.5M |
| blackrock, inc. | 5,064,180 | $342.7M |
| fmr llc | 3,764,844 | $254.8M |
| vanguard portfolio management llc | 3,095,098 | $209.5M |
| caption management, llc | 2,758,880 | $186.7M |
| state street corp | 2,647,054 | $179.2M |
| foresite capital management vi llc | 2,221,474 | $150.3M |
| geode capital management, llc | 1,596,864 | $108.1M |
Showing top 10 of 235 institutional holders of CG Oncology, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in CG Oncology, Inc.'s pipeline?
CG Oncology, Inc. (CGON) has 33 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CG Oncology, Inc.'s lead drug candidate?
CG Oncology, Inc.'s most advanced tracked candidate is Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5 (Phase 2) for Colorectal Carcinoma.
What is CG Oncology, Inc.'s next catalyst?
CG Oncology, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuva" — expected April 1, 2027.
What is CG Oncology, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CG Oncology, Inc. has approximately 54.4 months of cash runway.
What is CG Oncology, Inc.'s market capitalization?
CG Oncology, Inc.'s market capitalization is approximately $5.3B.
Get the full picture on CG Oncology, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.